Agmatine ameliorates lipopolysaccharide induced depressive-like behaviour in mice by targeting the underlying inflammatory and oxido-nitrosative mediators

Pharmacology Biochemistry and Behavior

Volumn 149, Issue , 2016, Pages 1-8

  Gawali, Nitin B ^a   Bulani, Vipin D ^a   Chowdhury, Amrita A ^a   Deshpande, Padmini S ^a   Nagmoti, Dnyaneshwar M ^a   Juvekar, Archana R ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Agmatine; BDNF; Depressive like behaviour; Lipopolysaccharide; Oxidative stress; Pro inflammatory cytokines

Indexed keywords

AGMATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; IMIPRAMINE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPRESSION; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; FORCED SWIM TEST; HIPPOCAMPUS; IMMOBILIZATION; LIPID PEROXIDATION; LOCOMOTION; MALE; MOUSE; MOUSE MODEL; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; TAIL SUSPENSION TEST; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NITROSATION; PHYSIOLOGY; PROCEDURES;

AGMATINE; ANIMALS; DEPRESSION; DRUG DELIVERY SYSTEMS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; NITROSATION; OXIDATIVE STRESS;

EID: 84979940411     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2016.07.004     Document Type: Article

References (71)

1. Adachi, M., Barrot, M., Autry, A.E., Theobald, D., Monteggia, L.M., Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol. Psychiatry 63:7 (2008), 642–649.
2. Ahn, S.K., Hong, S., Park, Y.M., Choi, J.Y., Lee, W.T., Park, K.A., Lee, J.E., Protective effects of agmatine on lipopolysaccharide-injured microglia and inducible nitric oxide synthase activity. Life Sci. 91 (2012), 1345–1350.
3. Aricioglu, F., Regunathan, S., Agmatine attenuates stress-and lipopolysaccharide induced fever in rats. Physiol. Behav. 85 (2005), 370–375.
4. Aricioglu, F., Kan, B., Yıllar, O., Korcegez, E., Berkman, K., Effect of agmatine on electrically and chemically induced seizures in mice. Ann. N. Y. Acad. Sci. 1009 (2003), 141–146.
5. August, M., Viossat, I., Marin, J.G., Chabrier, P.E., Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn. J. Pharmacol. 69 (1995), 285–287.
6. Aydemir, C., Yalcin, E.S., Aksaray, S., Kisa, C., Yildirim, S.G., Uzbay, T., Goka, E., Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006), 1256–1260.
7. Bhutada, P., Mundhada, Y., Humane, V., Rahigude, A., Deshmukh, P., Latad, S., Jain, K., Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 37:1 (2012), 96–105.
8. Biesmans, S., Meert, T.F., Bouwknecht, J.A., Acton, P.D., Davoodi, N., De Haes, P., Systemic immune activation leads to neuroinflammation and sickness behaviour in mice. Mediat. Inflamm., 2013, 2013, 271359.
9. Brocardo, P.D., Budni, J., Lobato, K.R., Kaster, M.P., Rodrigues, A.L.S., Antidepressant-like effect of folic acid: involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur. J. Pharmacol. 598 (2008), 37–42.
10. Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., Karam, A.N., Kaur, J., Kostyuchenko, S., Lepine, J.P., Levinson, D., Matschinger, H., Mora, M.E., Browne, M.O., PosadaVilla, J., Viana, M.C., Williams, D.R., Kessler, R.C., Cross- national epidemiology of DSM-IV major depressive episode. BMC Med 9 (2011), 90–106.
11. Brunoni, A.R., Lopes, M., Fregni, F., A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 11:8 (2008), 1169–1180.
12. Castrén, E., Rantamäki, T., Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment. CNS Drugs 24:1 (2010), 1–7.
13. Cryan, J.F., Mombereau, C., Vassout, A., The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 29 (2005), 571–625.
14. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9 (2008), 46–56.
15. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
16. Draper, H.H., Squires, E.J., Mahmoodi, H., Wu, J., Agarwal, S., Hadley, M., A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic. Biol. Med. 15 (1993), 353–363.
17. El-Agamy, D., Makled, M., Gamil, N., Protective effects of agmatine against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure in mice. Inflammopharmacology 22 (2014), 187–194.
18. Ellman, G.L., Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959), 70–77.
19. Espey, M.G., Kustova, Y., Sei, Y., Basile, A.S., Extracellular glutamate levels are chronically elevated in the brains of LP-BM5-infected mice: a mechanism of retrovirus-induced encephalopathy. J. Neurochem. 71 (1998), 2079–2087.
20. Eyre, H., Baune, B.T., Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 37 (2012), 1397–1416.
21. Freitas, A.E., Bettio, L.E., Neis, V.B., Santos, D.B., Ribeiro, C.M., Rosa, P.B., Farina, M., Rodrigues, A.L., Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 50 (2014), 143–150.
22. Freitas, A.E., Egea, J., Buendia, I., Gomez-Rangel, V., Parada, E., Navarro, E., Casas, A.I., Wojnicz, A., Ortiz, J.A., Cuadrado, A., Ruiz-Nuno, A., Rodrigues, A.L., Lopez, M.G., Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol. Neurobiol. 53:5 (2016), 3030–3045.
23. Gałecki, P., Szemraj, J., Bieńkiewicz, M., Florkowski, A., Gałecka, E., Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol. Rep. 61:3 (2009), 436–447.
24. Galecki, P., Galecka, E., Maes, M., Chamielec, M., Orzechowska, A., Bobinska, K., Lewinski, A., Szemraj, J., The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J. Affect. Disord. 138 (2012), 360–366.
25. Gawali, N.B., Chowdhury, A.A., Kothavade, P.S., Bulani, V.D., Nagmoti, D.M., Juvekar, A.R., Involvement of nitric oxide in anticompulsive-like effect of agmatine on marble-burying behaviour in mice. Eur. J. Pharmacol. 770 (2016), 165–171.
26. Gawryluk, J.W., Wang, J.F., Andreazza, A.C., Shao, L., Young, L.T., Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 14 (2011), 123–130.
27. Gilad, G.M., Salame, K., Rabey, J.M., Gilad, V.H., Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci. 58 (1996), 41–46.
28. Gong, Z.H., Li, Y.F., Zhao, N., Yang, H.J., Su, R.B., Luo, Z.P., Li, J., Anxiolytic effect of agmatine in rats and mice. Eur. J. Pharmacol. 550 (2006), 112–116.
29. Guan, Z., Fang, J., Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav. Immun. 20 (2006), 64–71.
30. Haenisch, B., Bönisch, H., Cichon, S., Allam, J.P., Novak, N., Molderings, G.J., Effects of exogenous agmatine in human leukemia HMC-1 and HL-60 cells on proliferation, polyamine metabolism and cell cycle. Leuk. Res. 35:9 (2011), 1248–1253.
31. Halaris, A., Plietz, J., Agmatine metabolic pathway and spectrum of activity in brain. CNS Drugs 21:11 (2007), 885–900.
32. Halaris, A., Zhu, H., Feng, Y., Piletz, J.E., Plasma agmatine and platelet imidazoline receptors in depression. Ann. N. Y. Acad. Sci. 881 (1999), 445–451.
33. Ji, W.W., Wang, S.Y., Ma, Z.Q., Li, R.P., Li, S.S., Xue, J.S., Li, W., Niu, X.X., Yan, L., Zhang, X., Fu, Q., Qu, R., Ma, S.P., Effects of perillaldehyde on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 116 (2014), 1–8.
34. Kheir-Eldin, A.A., Motawi, T.K., Gad, M.Z., Abd-ElGawad, H.M., Protective effect of vitamin E, beta-carotene and N-acetylcysteine from the brain oxidative stress induced in rats by lipopolysaccharide. Int. J. Biochem. Cell Biol. 33 (2001), 475–482.
35. Kim, Y.K., Lee, H.P., Won, S.D., Park, E.Y., Lee, H.Y., Lee, B.H., Lee, S.W., Yoon, D., Han, C., Kim, D.J., Choi, S.H., Low plasma BDNF is associated with suicidal behaviour in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31:1 (2007), 78–85.
36. Kotagale, N.R., Taksande, B.G., Wadhwani, P.J., Palhade, M.W., Mendhi, S.M., Gawande, D.Y., Hadole, P.N., Chopde, C.T., Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. Pharmacol. Biochem. Behav. 100:3 (2012), 398–403.
37. Kotan, V.O., Sarandol, E., Kirhan, E., Ozkaya, G., Kirli, S., Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:5 (2011), 1284–1290.
38. Krishnan, V., Nestler, E.J., Animal models of depression: molecular perspectives. Curr. Top. Behav. Neurosci. 7 (2011), 121–147.
39. Lee, B.H., Kim, Y.K., The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 7 (2010), 231–235.
40. Li, X., Frye, M.A., Shelton, R.C., Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 37 (2012), 77–101.
41. Liu, T., Zhong, S., Liao, X., Chen, J., He, T., Lai, S., Jia, Y., A meta-analysis of oxidative stress markers in depression. PLoS One, 10, 2015, e0138904.
42. Lopresti, A.L., Maker, G.L., Hood, S.D., Drummond, P.D., A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 48 (2014), 102–111.
43. Maes, M., Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 19 (1995), 11–38.
44. Maes, M., Depression is an inflammatory disease, but cell mediated immune activation is the key component of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35:3 (2011), 664–675.
45. Maes, M., Galecki, P., Chang, Y.S., Berk, M., A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 (2011), 676–692.
46. Maes, M., Song, C., Yirmiya, R., Targeting IL-1 in depression. Expert Opin. Ther. Targets 6 (2012), 1097–1112.
47. Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., Brunello, N., Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 21 (2006), 227–231.
48. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65 (2009), 732–741.
49. Muller, N., Schwarz, M.J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Muller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.J., Arolt, V., Riedel, M., The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11 (2006), 680–684.
50. Murray, C.J., Lopez, A.D., Evidence-based health policy—lessons from the global burden of disease study. Science 274 (1996), 740–743.
51. Na, K.S., Lee, K.J., Lee, J.S., Cho, Y.S., Jung, H.Y., Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 20 (2013), 79–85.
52. O'Connor, J.C., Lawson, M.A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522.
53. Ohgi, Y., Futamura, T., Kikuchi, T., Hashimoto, K., Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol. Biochem. Behav. 103 (2013), 853–859.
54. Porsolt, R.D., Le Pichon, M., Jalfre, M., Depression: a new animal model sensitive to antidepressant treatments. Nat Rev Neurosci 266 (1977), 730–732.
55. Puntener, U., Booth, S.G., Perry, V.H., Teeling, J.L., Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. J. Neuroinflammation, 9, 2012, 146.
56. Reis, D., Regunathan, S., Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol. Sci. 21 (2000), 187–193.
57. Rizzo, S.S., Neal, S.J., Hughes, Z.A., Beyna, M., Rosenzweig-Lipson, S., Moss, S.J., Brandon, N.J., Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl. Psychiatry, 2, 2012, e199.
58. Sastre, M., Galea, E., Feinstein, D., Reis, D., Regunathan, S., Metabolism of agmatine in macrophages: modulation by lipopolysaccharide and inhibitory cytokines. Biochem. J. 330 (1998), 1405–1409.
59. Semmler, A., Okulla, T., Sastre, M., Dumitrescu-Ozimek, L., Heneka, M.T., Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J. Chem. Neuroanat. 30 (2005), 144–157.
60. Sluzewska, A., Rybakowski, J., Bosmans, E., Sobieska, M., Berghmans, R., Maes, M., Wiktorowicz, K., Indicators of immune activation in major depression. Psychiatry Res. 64 (1996), 161–167.
61. Steru, L., Chermat, R., Thierry, B., Simon, P., The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:3 (1985), 367–670.
62. Sulakhiya, K., Kumar, P., Jangra, A., Dwivedi, S., Hazarika, N.K., Baruah, C.C., Lahkar, M., Honokiol abrogates lipopolysaccharide-induced depressive-like behaviour by impeding neuroinflammation andoxido-nitrosative stress in mice. Eur. J. Pharmacol. 744 (2014), 124–131.
63. Tracey, W.R., Tse, J., Carter, G., Lipopolysaccharide induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J. Pharmacol. Exp. Ther. 282:3 (1995), 1011–1015.
64. Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., Cella, D., Krishnan, R., Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo controlled randomised phase III trial. Lancet 367 (2006), 29–35.
65. Uzbay, T.I., The pharmacological importance of agmatine in the brain. Neurosci. Biobehav. Rev. 36 (2012), 502–519.
66. Varambally, S., Naveen, G.H., Rao, M.G., Thirthalli, J., Sharma, R., Christopher, R., Gangadhar, B.N., Low serum brain derived neurotrophic factor in non-suicidal out-patients with depression: relation to depression scores. Indian J. Psychiatry 55:3 (2013), S397–S399.
67. Wang, W.P., Iyo, A.H., Miguel-Hidalgo, J., Regunathan, S., Zhu, M.Y., Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res. 1084 (2006), 210–216.
68. Zhang, J.C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.X., Shirayama, Y., Hashimoto, K., Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol, 18(4), 2015, pyu077.
69. Zhu, M.Y., Piletz, J.E., Halaris, A., Regunathan, S., Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cell. Mol. Neurobiol. 23 (2003), 865–872.
70. Zomkowski, A.D.E., Hammes, L., Lin, J., Calixto, J.B., Santos, A.R.S., Rodrigues, A.L.S., Agmatine produces antidepressant-like effects in two models of depression in mice. Neuro Report 13 (2002), 387–391.
71. Zomkowski, A.D.E., Rosa, A.O., Lin, J., Santos, A.R.S., Calixto, J.B., Rodrigues, A.L.S., Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res. 1023 (2004), 253–263.